OUR PRODUCTS

ibs-smart™️ is an ELISA blood test that measures the levels of two antibodies known to be elevated in patients with post-infectious irritable bowel syndrome (IBS). 

 

The test offers physicians an optimized diagnosis protocol for diarrhea-predominant and mixed-type irritable bowel syndrome (IBS-D and IBS-M).

 

For the 10-15% of the worldwide population that suffers from IBS,  ibs-smart™️ can offer a clear diagnosis, prevent potentially unnecessary invasive procedures, and set a faster path to treatment.  

The test is based on a 2,500-patient study conducted at Cedars-Sinai Medical Center. Gemelli Biotech has the exclusive license from Cedars-Sinai to bring this test to market and continues to innovate the test in alignment with ongoing research into the pathophysiology of IBS.

 

To learn more, visit: www.ibssmart.com

ibs-smart™

IS THE SECOND-
GENERATION BLOOD TEST FOR IBS

trio-smart™ PROVIDES THE COMPLETE FERMENTED GAS PROFILE OF THE MICROBIOME  

The trio-smart™ breath test measures the levels of hydrogen, methane, and – for the first time - hydrogen sulfide in the breath of patients after lactulose or glucose consumption.

trio-smart™ aids in the in the identification of small intestinal bacterial overgrowth (SIBO), intestinal methanogenic overgrowth (IMO) and excess hydrogen sulfide. 

Using best-in-class breath testing technology, trio-smart™ is the only breath test to measure hydrogen sulfide, which correlates to diarrhea.

To learn more, visit www.triosmartbreath.com

sclero-smart™️ measures the levels of an antibody, anti-vinculin, that is elevated in up to 38% of patients with systemic sclerosis and scleroderma. This prevalence is higher than that of any other marker commonly used in the diagnosis of scleroderma.

 

Elevated levels of anti-vinculin ​are also predictive of pulmonary hypertension and gastrointestinal complications. No other marker currently available is reliable in predicting the involvement of the GI system.

The connection between anti-vinculin and scleroderma also suggests that the gut microbiome could hold the key to new diagnostic and therapeutic tools for scleroderma. 

 

To learn more, visit: www.sclerosmart.com

sclero-smart

AIDS IN THE DIAGNOSIS OF SCLERODERMA 

™️

STAY TUNED FOR MORE